Abbreviations
- AFP:
-
Alpha fetoprotein
- CRC:
-
Colorectal cancer
- CTL:
-
Cytotoxic T lymphocyte
- CTLA:
-
Cytolytic T lymphocyte-associated
- DC:
-
Dendritic cell
- GBM:
-
Glioblastoma multiformae
- GC:
-
Glucocorticoids
- GM-CSF:
-
Granulocyte–macrophage CSF
- HCC:
-
Hepatocellular carcinoma
- IDO:
-
Indoleamine 2,3-dioxygenase
- IFITM:
-
Interferon-inducible transmembrane protein family
- IFN-γ:
-
Interferon gamma
- IL-1:
-
Interleukin 1
- MAPK:
-
Mitogen-activated protein kinase
- MDSC:
-
Myeloid-derived suppressor cell
- MHC:
-
Major histocompatibility complex
- MM:
-
Multiple myeloma
- MMP:
-
Matrix metalloproteinases
- MSC:
-
Mesenchymal stem cell
- PBMC:
-
Peripheral blood mononuclear cell
- PD-1:
-
Programmed death 1 receptor
- PD-L1:
-
Programmed death ligand 1
- RCC:
-
Renal cell carcinoma
- SOCS3:
-
Suppressor of cytokine signaling-3
- STAT:
-
Signal transducer and activator of transcription
- TAA:
-
Tumor-associated antigen
- TAM:
-
Tumor-associated macrophage
- TAN:
-
Tumor-associated neutrophil
- TCR:
-
T cell receptor for Ag
- TEX:
-
Tumor-derived exosomes
- TGF:
-
Transforming growth factor
- TIL:
-
Tumor-infiltrating lymphocyte
- TIMC:
-
Tumor-infiltrating myeloid cell
- TLS:
-
Tertiary lymphoid structures
- TME:
-
Tumor microenvironment
- TNF:
-
Tumor necrosis factor
- TRAIL:
-
TNF-related apoptosis-inducing
- Treg:
-
Regulatory T cell
- UCP2:
-
Uncoupling protein 2
Acknowledgments
We thank for generous support of the CITIM meeting: CTL (Cellular Technology Ltd), Europe GmbH, Bonn, Germany; GTCbio (Global Technology Community), Monrovia, CA, USA; Immatics Biotechnologies GmbH, Tübingen, Germany; PIVAC (Progress in Vaccination against Cancer); Springer Science + Business Media B.V.; Cancer Immunology and Immunotherapy (Springer); The Journal of Immunotoxicology (Taylor & Francis); eBioscience Affimetrix; CCNF (Cure Cancer Now Foundation), Los Angeles, CA, USA; SITC (Society for Immunotherapy of Cancer), Milwaukee, WI, USA; Immudex, Copenhagen, Denmark; MSD; Merck Sharp & Dohme, Sandoz Lek Pharmaceuticals d.d., Ljubljana, Slovenia; innovative drugs d.o.o., Ljubljana, Slovenia; Merck, d.o.o., Ljubljana, Slovenia; AstraZeneca, UK Limited, subsidiary in Ljubljana, Slovenia; Sanolabor, d.o.o., Ljubljana, Slovenia; Association of Radiology and Oncology, Ljubljana, Slovenia; Carl Zeiss d.o.o., Ljubljana, Slovenia; City Municipality of Ljubljana, Slovenia; Kemomed, d.o.o., Kranj, Slovenia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors state no conflicts of interest.
Additional information
This meeting report is a summary of presentations from the Fourth International Conference on Cancer Immunotherapy and Immunomonitoring, CITIM 2015, published together with a series of Focussed Research Reviews based on lectures given at the conference.
Rights and permissions
About this article
Cite this article
Aptsiauri, N., Jewett, A., Hurwitz, A.A. et al. Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia. Cancer Immunol Immunother 65, 875–883 (2016). https://doi.org/10.1007/s00262-016-1795-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-016-1795-8